Search result6 min read

EGFR vs ERBB2: dependency and drugs compared

EGFR vs ERBB2 in DepMap Chronos data and drug annotations: 224 of 1178 EGFR-dependent lines versus 177 for ERBB2, and 118 versus 59 known drugs.

Data as of November 6, 2026 · By the BioQ team

BioQ results page for the query EGFR, showing CRISPR dependency by lineage and a table of known drugs with their sources.

In the DepMap release depmap_24q4, an EGFR knockout reduces viability in 224 of 1178 cell lines (19.0%), against 177 (15.0%) for ERBB2. Neither gene is common essential. EGFR has 118 known drugs and ERBB2 has 59, and Neratinib, Lapatinib and Afatinib appear in both lists. All data are as of 2026-11-06.

What we asked: EGFR vs ERBB2 on dependency and drugs

EGFR and ERBB2 are paralogs in the same receptor tyrosine kinase family, and many kinase inhibitors hit both. We wanted two comparisons, both run with the same blocks for each gene:

  • Dependency: how often a CRISPR knockout lowers viability across cancer cell lines, and in which lineages.
  • Drugs: which compounds are annotated for each gene, at what clinical stage, and with what exact potency.

The dependency blocks use the Chronos gene effect. A more negative value means the knockout reduced viability more. A line counts as dependent when its effect is at or below a named cut-off. That cut-off is a constant chosen by the analysis, not a property of the data. The drug blocks combine Open Targets, ChEMBL, the Drug Repurposing Hub and ClinicalTrials.gov.

What BioQ returned

Dependency by lineage

Across all 1178 cell lines, EGFR has 224 dependent lines (19.0%) and a mean gene effect of -0.294. ERBB2 has 177 dependent lines (15.0%) and a mean of -0.329. EGFR therefore has more dependent lines, while ERBB2 has the slightly more negative mean. Both are flagged as not common essential.

The five lineages with the most negative mean effect for EGFR:

LineageCell linesDependent% dependentMean gene effect
Head and Neck775166.2-0.702
Prostate10660-0.696
Biliary Tract351748.6-0.561
Cervix18738.9-0.434
Esophagus/Stomach692739.1-0.422

The same view for ERBB2:

LineageCell linesDependent% dependentMean gene effect
Breast531834-0.643
Head and Neck773545.5-0.509
Esophagus/Stomach691826.1-0.476
Biliary Tract35925.7-0.431
Pancreas471123.4-0.425

Drugs

For EGFR, BioQ lists 118 drugs and shows the top 6 here:

DrugMax clinical stageMechanismBest exact pChEMBLTypeTrials by name
OsimertinibAPPROVALEpidermal growth factor receptor erbB1 inhibitor11.7IC50188
AfatinibAPPROVALEpidermal growth factor receptor erbB1 inhibitor11IC50112
MobocertinibAPPROVALEpidermal growth factor receptor erbB1 inhibitor11IC504
NeratinibAPPROVALEpidermal growth factor receptor erbB1 inhibitor10.7IC5069
ErlotinibAPPROVALEpidermal growth factor receptor erbB1 inhibitor10.54IC50355
LapatinibAPPROVALEpidermal growth factor receptor erbB1 inhibitor10.22IC50144

For ERBB2, BioQ lists 59 drugs. The top 6 are Neratinib (exact pChEMBL 9.0, IC50), Lapatinib (8.8, KI), Afatinib (8.7, IC50), Tucatinib (8.7, IC50), Lapatinib Ditosylate (8.52, IC50) and Afatinib Dimaleate (8.3, KD). All six have a maximum clinical stage of APPROVAL.

BioQ answer for EGFR with the drug table listing maximum clinical stage, mechanism and exact pChEMBL values
The drug block for EGFR as BioQ displays it, with the source named for each layer.

What it means and how to read it

Where the two genes are alike. Both are non-common-essential, so a knockout hurts only a subset of lines. Head and Neck, Biliary Tract and Esophagus/Stomach appear in the top five for both genes. Head and Neck is the clearest overlap. EGFR has 51 dependent lines of 77 (66.2%), and ERBB2 has 35 of 77 (45.5%).

Where they differ. The strongest EGFR lineages after Head and Neck are Prostate (6 of 10, 60.0%) and Biliary Tract (17 of 35, 48.6%). The ERBB2 list is led by Breast, with 18 of 53 lines dependent (34.0%) and a mean of -0.643. Breast does not appear in the EGFR top five. Prostate and Cervix are absent from the ERBB2 top five, and Pancreas is absent from the EGFR top five. In Esophagus/Stomach, EGFR has 27 of 69 lines dependent (39.1%) and ERBB2 has 18 of 69 (26.1%), yet the ERBB2 mean of -0.476 is more negative than the EGFR mean of -0.422. A lower share of dependent lines does not always mean a weaker average effect.

Drug overlap and selectivity. Neratinib, Lapatinib and Afatinib are annotated for both genes, which fits the shared family. Their listed exact pChEMBL values are higher under EGFR than under ERBB2:

  • Neratinib: 10.7 for EGFR, 9.0 for ERBB2.
  • Lapatinib: 10.22 for EGFR, 8.8 for ERBB2.
  • Afatinib: 11.0 for EGFR, 8.7 for ERBB2.

Treat this as a pointer for EGFR ERBB2 selectivity, not a measured ratio. The values are single highest exact measurements, and the assay type differs in places. Lapatinib is IC50 for EGFR but KI for ERBB2. Tucatinib appears among the top six for ERBB2 with 56 trials by name, but not among the top six for EGFR. That list is truncated, so it does not show whether Tucatinib is absent from the full EGFR set.

The trial counts are matched by drug name, not by gene. Neratinib (69), Lapatinib (144) and Afatinib (112) therefore show identical counts under both genes. They also do not separate trials in EGFR-driven disease from trials in ERBB2-driven disease.

How to reproduce it in BioQ

BioQ drew on 2 distinct resources for this comparison. It ran 4 engine queries in 1.09 engine seconds, and every block names its source and release. Doing the same by hand means matching gene identifiers, lineage definitions and drug names across separate portals.

  1. Open BioQ and enter the query below.
  2. Read the dependency block (DepMap, Chronos) and the drug block for EGFR.
  3. Repeat with ERBB2 in place of EGFR, so both genes use the same blocks and the same parameters.
  4. Compare lineage rows and shared drug names. Check the assay type next to each pChEMBL value before comparing potencies.
EGFR

Open this query in BioQ

Limits: what the data do not show

  • Cell lines are not tumors. A dependency in a cultured line does not show the same dependency in a patient.
  • The cut-off is a convention. The dependent counts and percentages depend on the named threshold. The mean gene effect does not.
  • Small lineages are noisy. Prostate has only 10 lines, so its 60.0% rests on very few observations.
  • Top-five lists are truncated. A lineage missing from one list may still show a dependency. It just ranks lower by mean effect.
  • Potency values are not matched pairs. The pChEMBL figures are single exact measurements from different assays, so they do not give a clean selectivity ratio.
  • Annotation is not evidence of benefit. The drug layer shows maximum clinical stage and potency, not outcomes or suitability for any patient. Trial counts by name do not link a trial to a gene.

Data and method

The numbers on this page were read from the BioQ engine on 2026-11-06 (4 queries, 1.1 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

/depmap, /drugs

Run the same query yourself: EGFR

For research use only. This page summarises public data and is not medical advice.

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

Queries used

Frequently asked questions

How many cell lines depend on EGFR compared with ERBB2 in DepMap?

In depmap_24q4, 224 of 1178 cell lines (19.0%) are dependent on EGFR, and 177 of 1178 (15.0%) are dependent on ERBB2. Neither gene is flagged as common essential.

Which lineages are most dependent on EGFR and on ERBB2?

For EGFR, Head and Neck leads with 51 of 77 lines dependent (66.2%). For ERBB2, Breast leads with 18 of 53 (34.0%). Head and Neck also appears in the ERBB2 top five, at 35 of 77 (45.5%).

How many drugs are known for EGFR versus ERBB2?

BioQ lists 118 drugs for EGFR and 59 for ERBB2. Neratinib, Lapatinib and Afatinib appear in the top six for both genes.

Do the pChEMBL values show EGFR ERBB2 selectivity?

For Neratinib, Lapatinib and Afatinib, the listed exact pChEMBL is higher for EGFR (10.7, 10.22, 11.0) than for ERBB2 (9.0, 8.8, 8.7). These are single measurements, and Lapatinib's ERBB2 value is a KI while its EGFR value is an IC50, so they are not a matched selectivity ratio.

How long does the EGFR vs ERBB2 comparison take in BioQ?

The 4 engine queries took 1.09 engine seconds in total and drew on 2 distinct resources.

Sources

  1. Dataset DepMap CRISPR Chronos gene effect (24Q4)
  2. Dataset Open Targets Platform; ChEMBL; Drug Repurposing Hub

Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.

More from the blog